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In consultation the authors were requested to evaluate a middle-aged diabetic woman for an
apparent episode ofbiliary sepsis. The patient had been admitted to thedermatology service with
a four-day history ofrash and pruritus. This was initially thought to represent an allergic reaction
to dicloxacillin in someone with a previous history of penicillin hypersensitivity. Persistent right
upper quadrant pain, fevers, elevations of serum alkaline phosphatase, and a radionuclide scan
which did not demonstrate a functioning gall bladder led to a cholecystectomy for acute
cholecystitis and possible biliary sepsis. This diagnosis was not confirmed. Ultimately, this case
illustrated the need to review carefully recent changes in anypatient'sdrug regimen. Reactions to
commonly prescribed agents may cause syndromes which are difficult to distinguish from
episodes ofapparent sepsis.
CASE PRESENTATION
A 52-year-old black woman with non-insulin dependent diabetes mellitus docu-
mented for over two years was admitted to the Dermatology Service at Yale-New
Haven Hospital with a chiefcomplaint ofrash and pruritus offour days' duration.
She related the onset of her illness to shampooing with a mixture of Kwell and rug
shampoo in an attempt tostraighten her hair three weeks prior toadmission. Sincethat
time she had experienced fatigue, diminishing appetite, and intermittent cold sweats.
Four days prior to admission, she noted pruritus in the left axilla associated with an
erythematous rash. A physician prescribed a topical cream and lorazepam. The
following day she visited a local hospital emergency room because of persistent rash
and the onset offever. Her temperature was noted to be 1020 F. She wasgiven a topical
steroid cream and dicloxacillin despite a history of pencillin allergy. During the next
two days the patient's fever persisted. The rash spread to involve both her trunk and
extremities. She was referred to the Dermatology Service at Yale-New Haven
Hospital and admitted for evaluation. Review of symptoms was otherwise unremark-
able except for ill-defined right-sided abdominal discomfort which had been present
for several weeks.
Her past medical history was remarkable for diabetes mellitus, controlled with oral
hypoglycemic agents. She had been treated with acetohexamide (Dymelor); however,
four weeks prior to admission her medication was changed to chlorpropamide
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(Diabinese). A known peptic ulcer had been inactive for several years. There was no
prior history ofatopy, asthma, eczema, psoriasis, or other skin disease. She had smoked
one pack of cigarettes weekly for several years and had a past history of alcohol
abuse.
The patient was aware of her allergy to penicillin. In the 1950s she received an
intramuscular injection of penicillin after which she developed a generalized rash.
There was no history ofrecent travel, nor were there any pets at home. Medications on
admission included dicloxacillin, chlorpropamide, and a topical steroid cream.
The patient was described as well-developed, well-nourished, and in no acute
distress, with a temperature of 102.20 F. Her skin was remarkable for generalized
urticaria, with erythematous papules and plaques covering 60-70 percent of her body
surface. Some plaque-like lesions contained pustules. There were numerous moist,
weeping vesicles on erythematous bases found on the neck. Palms and soles were not
involved. The nails, scalp, and mucous membranes were normal. She had no lymphade-
nopathy. Her abdomen was soft and non-tender without any appreciable organomega-
ly. Neurological examination was unremarkable.
Laboratory data on admission included a white blood count of 5,700cells/Al with a
differential count of 69 percent segmented neutrophils, 22 percent band forms, 5
percent lymphocytes, 2 percent monocytes, and 2 percent eosinophils. Her hematocrit
was 41.5 percent and platelet count was 139,000/,.l. Prothrombin time and partial
thromboplastin time were within normal limits. Sedimentation rate (ESR) was 42
mm/hour (normal < 20). Serum chemistries included a serum sodium of 125 meq/L
and bicarbonate of 17.5 meq/L. Blood urea nitrogen and serum creatinine were within
normal limits, and her serum glucose was 423 mg %. Her urine specific gravity was
1.036 g/ml; urine pH was 5.0 with 2+ protein, 3+ glucose, moderate bile, and
negative reactions for ketones and occult blood. Microscopic examination ofher urine
showed 0-1 white blood cells per hpf, and 0-1 red blood cells per hpf. Casts and
bacteria were not seen. Arterial blood gases while the patient was breathing room air
demonstrated a pH of7.43, P02 of 105 mm Hg, pCO2 of27 mm Hg, and a bicarbonate
of 17.2 meq/L. Chest X-ray showed plate-like atelectasis in the left lower lobe; no
infiltrates were apparent. Except for sinus tachycardia at a rate of 100, her electrocar-
diogram was normal.
DR. ROBERT BALTIMORE (Associate Professor ofPediatrics and Epidemiology, Yale
University School ofMedicine): Were any pustular lesions unroofed, Gram-stained,
and cultured?
DR. DONALD F. HEIMAN (Postdoctoral Fellow in Infectious Diseases, Yale University
School ofMedicine): Yes. Gram stains of the pustular skin lesions were done and no
organisms were noted.
DR. BALTIMORE: In a paitent such as this, presenting with fever and a vesiculo-pustular
eruption, viral infection warrants serious consideration. This presentation is consistent
with eczema herpeticum which occurs in patients with chronic eczema. Was there any
past medical history or family history ofeczema?
DR. HEIMAN: There was no family history ofdermatologic disease obtained. Other than
a rash at the time of penicillin administration 25 years ago, the patient had no prior
history ofskin diseases.
DR. GEORGE THORNTON (Clinical Professor ofMedicine, ChiefofMedicine, Water-
bury Hospital): I am very concerned about the presence of bile in her urine, which
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suggests that a more generalized disease process is occuring. Secondary syphillis
certainly can involve both liver and skin and cause fever, as can sarcoidosis.
DR. HEIMAN: A serum VDRL test was nonreactive. She had no history of pulmonary,
visual, orjoint symptoms and her chest X-ray did not demonstrate any abnormalities
consistent with sarcoidosis, but thatdiagnosis was considered. Atthetimeofadmission
to the hospital the leading diagnosis was pustular drug eruption secondary to
dicloxacillin in a patient with hypersensitivity to penicillin.
APHYSICIAN: The patient actually had an axillary rash and fever prior to the time that
dicloxacillin was prescribed. Is that not correct?
DR. HEIMAN: That is correct. At the time ofadmission, the patient's dicloxacillin and
chlorpropamide were discontinued. She was treated with regular (crystalline zinc)
insulin, fluid and electrolyte replacement. The topical steroids were continued. On the
second hospital day, thepatient remained febrile. Blood andurineculturesobtained on
admission were reported negative. On the third hospital day, scleral icterus was noted.
Total bilirubin was 7 mg/dl with a direct fractionof4.48 mg/dl. Lacticdehydrogenase
was 498 IU/L (normal 200-600). Serum glutamyloxaloacetate transaminase was 31
IU/L (normal 15-35), alkaline phosphatase was 183 IU/L, (normal 10-70), and
serum amylase was 53 IU/dl (normal 40-150).
A PHYSICIAN: What was happening to her white blood cell count and hematocrit? If
hemolysis was also present, associated with fever and skin rash, angioimmunoblastic
lymphadenopathy syndrome would be a consideration.
DR. HEIMAN: Her white blood cell count on the third hospital day was 10,500 cells/,ul
with a differential of 22 percent segmented neutrophils, 67 percent band forms, 7
percent lymphocytes, 2 percent monocytes, and 2 percent eosinophils. Her hematocrit,
which was 41.5 percent on admission, dropped to the 35 percent range after hydration
and remained stable at that level. A Coombs test was not performed.
DR. BALTIMORE: Was a skin biopsy done?
DR. HEIMAN: Yes, a skin biopsy was performed on the second hospital day. However,
the results of that biopsy were not yet available. A medical consultant was concerned
because of the presence of punch tenderness over the right upper quadrant in this
febrile, jaundiced patient with diabetes. Both surgical consultation and HIDA
99mTc-labeled lidofenin scan were recommended. The working diagnosis was cholecys-
titis, with probable cholangitis. Vancomycin and gentamicin were administered to
treat apotential hepatobiliary infection. Earlyon thefourth hospitalday, a HIDA scan
was performed. It showed no visualization of the gallbladder or bile ducts; however,
radionuclide activity was detected in the small intestine. The scan was thought to be
compatible with acute cholecystitis without evidenceofcommon bile duct obstruction.
An ultrasound examination of the abdomen demonstrated a small, thick-walled gall
bladder. There was slight dilatation of the intrahepatic ducts. The diameter of the
common bile duct was measured at the upper limits of normal. The ultrasound
examination was thought to suggest cholecystitis. Kidneys, spleen, and pancreas were
normal. How would you proceed at thisjuncture?
DR. MARY JEAN AHERN (Assistant Clinical Professor of Medicine, Yale University
School ofMedicine): How ill did the patient look?
DR. HEIMAN: She appeared quite toxic with fevers to 1040 F. She complained only of
mild discomfort in her right upper quadrant without radiation to her back or
shoulders.
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DR. AHERN: I would certainly begin antibiotics because an infectious hepatobiliary
process is possible. I am not sure I would rush her to the operating room. The onset of
her illness suggests a disease other than acute cholecystitis.
DR. JOHN MELLORS (Assistant Professor of Medicine, Yale University School of
Medicine): The dermatologists' admitting diagnosis was a pustular drug eruption. At
the time ofadmission she had been taking dicloxacillin and chlorpropamide. All ofthe
patient's signs and symptoms could be explained by a systemic toxic reaction to either
of these agents. Is either associated with cholestasis and was a liver biopsy
considered?
DR. HEIMAN: Before that pertinent question was asked or answered, the patient was
taken to the operating room. A percutaneous liver biopsy was not performed since the
patient's toxic appearance was felt to warrant a laparotomy and cholecystectomy. She
was observed to have a grossly normal gall bladder, normal bile ducts, and liver. No
gall stones were found. A cholecystectomy and liver biopsy were performed.
On the first post-operative day the patient's fever reached 104OF and she developed
an intense erythroderma. Blood cultures remained negative. An infectious disease
consultation was requested. Physical examination revealed a well-nourished black
woman resting in her surgical ICU bed in mild distress from incisional pain. She had
diffuse erythema ofher skin with pustular lesions on her arms and legs. There were no
pustules on her palms or soles. Both her scalp and mucous membranes were normal.
Scleral icterus and bilateral subconjunctival hemorrhages, which had not been present
prior to surgery, were noted. The rest ofher examination was remarkable only for the
presence of a right-sided abdominal incision and some incisional tenderness. We
concluded that fever, dermatitis, and jaundice were all secondary to chlorpropamide
hypersensitivity and recommended stopping the antibiotics, since there was no
evidence ofinfection.
DR. FRANK BIA (AssociateProfessorofMedicine, Yale UniversitySchoolofMedicine):
What was most helpful to me and other members ofour service was her history ofrash
and fever occurring after she began taking chlorpropamide and prior to being started
on dicloxacillin. Shortly after beginning the chlorpropamide, she developed intense
pruritus, which she unfortunately associated with her shampooing. The question just
raised by Dr. Mellors was an important one in this case. Aware of previous reports
describing rash and fever from chlorpropamide hypersensitivity, we looked into the
question ofcholestasis. In addition to intense pruritus, rash, and fever, chlorpropamide
has been associated with cholestaticjaundice in 0.5 percent ofpatients given the drug.
We feltconfident about our recommendation tostopantibiotics immediately and begin
a course ofcorticosteroids, especially in light ofthe normal gall bladder and bile ducts
found at surgery. Had the ultrasound and HIDA examinations of gall bladder been
normal, I suspect the physicians caring for this patient might also have felt more
confident about ascribing this entire clinical picture to a drug reaction.
A PHYSICIAN: Isn't it possible that this patient simply passed a gall stone and had
transient biliary obstruction on that basis?
DR. HEIMAN: I suppose that is a possible explanation for her jaundice; however, that
would not explain her fever and cutaneous eruption. A hypersensitivity reaction to
chlorpropamide explained all aspects ofher presentation. Her antibiotics were stopped
and she was begun on oral prednisone, 60 mg daily. The skin biopsy (Fig. 1) showed a
superficial perivascular mixed-cell infiltrate. There was perifollicular infiltration as
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FIG. 1. Punch biopsy specimen of
skin from right forearm showing acute
pustular drug eruption (150 x). Note
the subcorneal pustule containing nu-
merous eosinophils (A), papillary der-
1; mal edema (B), and extravasated red
{; : blood cells indicating hemorrhage into
the dermis (C).
well. The epidermis had focal collections of polymorphonuclear leukocytes and
eosinophils above the stratum granulosum and was most consistent with a drug
hypersensitivity reaction.
The patient became afebrile after one day of steroid therapy and she remained
afebrile during the remainder of her hospital stay. Dermatitis quickly improved, and
erythroderma faded, although she eventually desquamated almost her entire skin
surface. As her serum bilirubin fell and her jaundice resolved, her serum alkaline
phosphatase level rose to a peak of 647 IU/L. Concomitantly, her amylase and lipase
rose as high as 585 IU/dl and 24 IU/ml (normal < 1.5), respectively. During this time
she had an excellent appetite and was feeling well. Prednisone was discontinued after
four days oftherapy because ofconcern that her rising serum amylase and lipase were
related to steroid therapy. Her blood eosinophil count rose after prednisone was
discontinued, reaching 4,200cells/,ul. A repeat abdominal ultrasound examination was
normal except for the absence ofa gall bladder. Within one month her serum alkaline
phosphatase, amylase, and lipase had returned to normal.
The intraoperative liver biopsy showed mild chronic portal triaditis with inflamma-
tion confined totheportal areas. There was some fatty change and nuclear anisocytosis
reflecting a nonspecific response to injury. There was no evidence of chronic active
hepatitis or cirrhosis.
A PHYSICIAN: Had the chlorpropamide been discontinued immediately after admis-
sion?
DR. HEIMAN: Yes. However, it should not be surprising that her hypersensitivity
reaction continued to evolve for several more days. The half-life ofchlorpropamide is
36 hours. Dr. Robert Levine will discuss chlorpropamide hypersensitivity in more
detail.
DISCUSSION
DR. ROBERTLEVINE (Postdoctoral Fellow in Endocrinology, Yale University School of
Medicine): Chlorpropamide is an oral hypoglycemic agent in the sulfonylurea class of
drugs. Shortly after chlorpropamide's release, in the late 1950s, several reports of
jaundice and hepatic damage associated with its use appeared [1,2]. While these
effects are listed in both the Physician's Desk Reference (PDR) and the manufactur-
er's literature, several current textbooks ofendocrinology and diabetology either fail to
consider them or mention them only in passing. A review oforal hypoglycemic agents
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published in 1977 parenthetically noted a 0.5 percent incidence oftransient cholestatic
jaundice, but did not indicate whether therapy was continued [3,4].
As in the patient under discussion, the jaundice is generally cholestatic, with
elevations of serum alkaline phosphatase out of proportion to the elevation of serum
transaminases. This pattern could easily be misinterpreted as biliary obstruction. The
onset ofclinical symptoms tends to occur within two to five weeks ofstarting therapy,
as in this case. Jaundice is frequently preceded or accompanied by high fever, toxic
appearance, malaise, nausea, anorexia, and vague abdominal pains. In many cases
there is a generalized erythematous maculopapular rash, which may progress to
scaling or diffuse exfoliative dermatitis. In many cases peripheral blood eosinophilia
has been noted [1].
The symptoms tend to resolve within a few days to a week of discontinuing the
medication. However, biochemical abnormalities, including elevated alkaline phospha-
tase and bilirubin, may not return to normal for several weeks to a month, and even
after stopping the medication, the laboratory abnormalities may worsen before they
improve [1,2]. Liver biopsies done on patients with chlorpropamide-induced jaundice
may show prominent bile stasis, particularly in centrilobular zones, with bile thrombi
and degeneration of liver cells. Hepatic architecture remains intact, but areas of focal
necrosis have been observed [5]. Some reports describe peri-portal inflammation
including eosinophilic infiltration [5]. Electron microscopy has shown electron-dense
mitochondrial inclusions, swollen and disrupted endoplasmic reticulum, dilated bile
canaliculi, and altered microvilli in undilated bile canaliculi [5]. Thesefindings are not
always present, and in some cases biopsies are normal [2].
It is still unclear whether cholestasis reflects an allergic or a toxic reaction. The
findings of a clinical latent period, rash, eosinophilia, and positive reactions following
rechallenge with the drug all suggest an allergic mechanism; however, in some cases
jaundice may occur without any ofthese associated findings. Whatever its mechanism,
the pathologic abnormality seems to be one of altered bile canaliculus permeability,
resulting in sludging, precipitation of bile salts, formation of bile plugs, and focal
obstruction [5].
Recently two second-generation oral hypoglycemic agents were released in the
United States: glyburide (Micronase, Diabeta) and glipizide (Glucotrol). Extensive
European experience indicates that one of their advantages is a lower frequency of
adverse reactions; hepatic toxicity rarely has been reported. In an early survey ofover
5,000 patients receiving these drugs, there were few liver function abnormalities
reported [6]. There has been one case report of cutaneous bullae and reversible
cholestaticjaundice associated with glyburide therapy [7], and an additional report of
fatal toxic erythema,jaundice, eosinophilia, and renal failure associated with necrotiz-
ing angiitis [7]. Both cases appeared to have been idiosyncratic reactions, and
second-generation agents continue to show a lower incidence ofside effects [8,9].
It has been suggested that the lower incidence of side effects observed with the
second-generation hypoglycemic agents may be due to their higher potency and lower
serum levels, as well as fewer drug interactions. The first-generation agentsare,polar
compounds which bind to albumin with ionic forces. Other anionic drugs such as
coumadin, nonsteroidal anti-inflammatory agents, or sulfonamides may displac'e the
first-generation agents from albumin, causing higher serum drug levels and hypogly-
cemia [10]. The second-generation agents are nonpolar, bind to albumin by non-ionic
forces, and cause fewer drug interactions [10,11]. In addition, the "Antabuse
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Syndrome," or facial flushing, which occurs in some patients who ingest alcohol while
taking chlorpropamide, has rarely been observed in patients taking the second-
generation hypoglycemic agents.
In summary, the clinical syndrome induced by the sulfonylureas, sulfonamides, or
other drugs causing intrahepatic cholestasis may mimic biliary obstructive disease
with symptoms of fever, toxicity, abdominal pain, nausea, vomiting, jaundice, and an
elevation ofserum alkaline phosphatase. A history ofdrug ingestion, or the presence of
rash or eosinophilia, should raise suspicions of a drug reaction. Some sources have
suggested routinely checking the patient's alkaline phosphatase levels during the first
few weeks ofchlorpropamide administration since the reaction is generally seen during
the first six weeks oftherapy.
A PHYSICIAN: Does cholestatic jaundice occur with tolazamide (Tolinase) administra-
tion?
DR. LEVINE: It does. While most frequently associated with chlorpropamide use,
cholestatic jaundice has been reported with all of the first-generation oral hypogly-
cemic agents. One study investigated cross-reactivity between agents and found that
some patients who had previously experienced chlorpropamide hepatotoxicity were
able to tolerate tolbutamide (Orinase) [1]. Other investigators report cross-reactivity
between agents [5].
ASTUDENT: What about sulfa drugs, i.e., the commonly used antibiotics?
DR. LEVINE: Similar pictures have been described with the sulfonamides. Descriptions
of sulfonylurea hepatotoxicity refer to the sulfonamides as the prototype for such
reactions.
A PHYSICIAN: Would you warn her not to take any sulfa medications again? For
example, should a urinary tract infection be so treated in the future?
DR. LEVINE: It would be best to consider her as having a sulfa allergy, especially with a
reaction this severe. The severity of reported reactions is variable. Obviously the ones
reported in the literature are among the most severe. However, there have been a
number manifested only by transient abnormalities of liver function tests. Such
patients don't present with the full clinical syndrome, and in these patients another
drug ofthe same class might be cautiously tried.
DR. HEIMAN: This case is an excellent illustration of the necessity to consider drug
hypersensitivity when a patient presents with an acute systemic illness, particularly if
associated with a rash. Had the diagnosis of chlorpropamide-induced cholestasis and
dermatitis been considered earlier in this case, the patient might have been spared a
laparotomy and its associated risks.
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